Welcome to our dedicated page for Hercules Capital news (Ticker: HTGC), a resource for investors and traders seeking the latest updates and insights on Hercules Capital stock.
Hercules Capital, Inc. (NYSE: HTGC) is a premier specialty finance company dedicated to providing senior secured loans to high-growth, venture capital-backed companies in technology-related markets. Established in December 2003, Hercules has positioned itself as a key player in the venture lending space, committing over $4.6 billion to more than 300 companies across various stages of development. The company focuses on sectors such as technology, biotechnology, life sciences, and sustainable and renewable energy.
Hercules Capital stands out by offering more than just financial support. The company provides vital access to its expansive network of contacts and invaluable business advice, helping entrepreneurial companies achieve significant milestones. Their investment portfolio includes a mix of structured debt with warrants, senior debt, and equity investments.
Recent achievements include a $35 million loan facility to SynOx Therapeutics Limited to support the development of emactuzumab, a next-generation monoclonal antibody for treating Tenosynovial Giant Cell Tumour (TGCT). Another notable investment is the $150 million financing to Harness, a Modern Software Delivery Platform company, to expand its platform with new modules and enhance its use of generative AI.
Hercules Capital’s strategic partnerships and financial solutions make it the lender of choice for venture-backed companies seeking reliable growth capital. The company’s financial stability and extensive industry expertise ensure that it remains a trusted partner for innovation-driven businesses looking to scale.
IVERIC bio, Inc. (Nasdaq: ISEE) has secured a $250 million term loan debt financing facility from Hercules Capital (NYSE: HTGC) and Silicon Valley Bank. This non-dilutive financing strengthens the company's balance sheet, allowing it to fund the potential launch of Zimura® (avacincaptad pegol) in the U.S., pending regulatory approval. The initial $50 million will be drawn in July 2022, with additional funds contingent on achieving performance milestones. Iveric plans to report data from the GATHER2 clinical trial in September 2022, crucial for Zimura's development.
Hercules Capital, Inc. (NYSE: HTGC) announced a supplemental cash distribution of
Hercules Capital, the leading specialty finance provider, announced a second quarter 2022 cash distribution of $0.35 per share. The record date is August 9, 2022, with payments made on August 16, 2022. The company's distribution policy aims to allocate approximately 90% to 100% of its taxable income. For the second quarter, 87.1% of the declared distributions were from current and accumulated earnings. Hercules has committed over $14 billion to more than 570 companies since its inception in December 2003.
Hercules Capital, Inc. (NYSE: HTGC) has announced a conference call scheduled for July 28, 2022, at 2:00 p.m. PT to discuss its second quarter 2022 financial results. The results will be released after market close the same day. Hercules Capital, a leader in providing senior secured loans to venture-backed companies, has committed over $14 billion to more than 570 companies since its inception in 2003. Investors can participate through a live webcast or via telephone registration.
Geron Corporation announces an expansion of its loan facility with Hercules Capital and Silicon Valley Bank, increasing access from $75 million to $125 million. This amendment allows for an additional $50 million in potential non-dilutive capital in 2023, crucial for the company as it anticipates top-line results from the Phase 3 IMerge trial in January 2023. Funding aims to support operations and potential commercialization of imetelstat until mid-2024.
Hercules Capital (NYSE: HTGC) announced the appointment of DeAnne Aguirre as an independent board member, effective June 23, 2022. With over 30 years of executive experience in managing complex business units, Aguirre will join the Nominating and Corporate Governance Committee. CEO Scott Bluestein highlighted her extensive industry experience as a valuable asset for the firm, especially as it expands its market reach. Aguirre's previous roles include being Managing Partner at PricewaterhouseCoopers and serving on the board of Cisive.
Hercules Capital has successfully closed two new debt financings, raising a total of $200 million. This includes $150 million in Class A Notes, which have a 4.95% fixed interest rate and mature on
Hercules Capital (NYSE: HTGC) has successfully increased its credit facilities, raising its MUFG facility from
The total combined credit capacity now stands at
Hercules Capital, Inc. (NYSE: HTGC) announced a BBB- investment grade credit rating from Fitch Ratings with a stable outlook. This rating acknowledges Hercules' diversified lending model and strong credit track record. Key highlights include a focus on first lien debt investments, a solid asset coverage ratio above 25%, and a flexible funding strategy. Since December 2003, Hercules has committed over
Hercules Capital, Inc. (NYSE: HTGC) will conduct its 2022 Annual Meeting of Stockholders virtually on June 23, 2022, at 9:00 a.m. Pacific Time. The proxy statement was sent on May 4, 2022, to shareholders of record as of April 25, 2022. Key voting matters include the election of two directors, an advisory vote on executive compensation, and the ratification of the independent accounting firm. Hercules Capital provides senior secured venture growth loans and has committed over $14 billion to over 570 companies since its inception in December 2003.
FAQ
What is the current stock price of Hercules Capital (HTGC)?
What is the market cap of Hercules Capital (HTGC)?
What does Hercules Capital, Inc. specialize in?
Which industries does Hercules Capital, Inc. focus on?
How much has Hercules Capital, Inc. committed since its inception?
What kind of financial products does Hercules Capital, Inc. offer?
Can you provide an example of a recent investment by Hercules Capital, Inc.?
Why do companies choose Hercules Capital, Inc.?
How does Hercules Capital, Inc. support its portfolio companies beyond financial investment?
What is a notable recent achievement of Hercules Capital, Inc.?
How does Hercules Capital, Inc. ensure its financial stability?